Key publications

Here are some outstanding key publications from group members, that have demonstrably influenced policy or opinion in Australia and around the world. For a full list of publications for MORE’s leadership team, click the links below:


Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. European Journal of Preventive Cardiology.

First study to estimate the projections of cardiovascular disease in Australia, using dynamic modelling.

Cost Effectiveness of Antenatal Lifestyle Interventions for Preventing Gestational Diabetes and Hypertensive Disease in Pregnancy. PharmacoEconomics Open.

First study to look the cost effectiveness of Antenatal life style interventions to prevent gestational Diabetes in Australia.


Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment? Atherosclerosis.

This novel decision economic model was first to consider genetic testing and the impact of high cholesterol from an early age, including treatment from childhood. Provided evidence that testing children and treating them early was a cost-saving over lifetime.

The costs of epilepsy in Australia: A productivity-based analysis. Neurology.

This study used our new measure (PALY) to report for the first time the lifetime cost and broader economic impact of epilepsy on productivity. It revealed that epilepsy exerts a greater economic and societal burden than other common diseases in Australia, and highlights an unmet clinical need.

Reducing caesarean delivery: An economic evaluation of routine induction of labour at 39 weeks in low-risk nulliparous women. Pediatrics and Perinatal Epidemiology.

First study internationally to conduct a full cost-effectiveness analysis of routine induction of labour at 39 weeks gestation amongst low-risk nulliparous women – a practice of international importance and current debate.

Financing Maternity and early childhood healthcare in The Australian Healthcare System: Costs to Funders in Private and Public Hospitals over the first 1000 days. International Journal of Health Policy and Management.

Identified the variation in patient charges for healthcare in Australia. Generated a large and sustained amount of media attention with articles in the SMH, the Age, Money Magazine, Financial Review, Mamma Mia, and SBS’s Insight program.

Implementing a national first-line management program for moderate-severe knee osteoarthritis in Australia: A budget impact analysis. Osteoarthritis Cartilage Open.

This analysis showed that a structured physiotherapy program for knee osteoarthritis could help people to delay or avoid knee replacement surgery, saving the Australian health system up to $690 million per year.

Lifetime risk of primary shoulder arthroplasty from 2008-2017: A population-level analysis using national registry data. Arthritis Care & Research.

First study to look at lifetime risk of primary shoulder arthroplasty anywhere in the world. Use of shoulder arthroplasty is growing faster than hip and knee arthroplasty and set to rise further.


Who experiences unmet need for mental health services and what other barriers to accessing healthcare do they face? Findings from Australia and Canada. International Journal of Health Planning and Management.

This publication led to then PhD candidate (Corscadden) being awarded a HARC Fellowship to travel throughout Europe to present her analysis framework at government health performance reporting agencies.

The cost of maternity care to public hospitals: a first 1,000 days perspective from Queensland. Australian Health Review.

Led to a series of invitations to speak at peak maternity services body in Australia to maternity service executives about cost variation in maternity care.

Productivity Burden of Hypertension in Australia. Hypertension.

First paper to highlight the total estimated productivity burden loss due to hypertension in Australia.

Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland. BMJ Open.

The first cost-effectiveness study using individual risk scores to assess the clinical utility of the Pill Protect test when screening first-time seekers of combined hormonal contraceptives at risk of deep vein thrombosis (DVT). The test was implemented in clinical practice and is now a reimbursed item in the Swiss healthcare system, improving patient outcomes and reducing health system costs. Beneficiaries are 89,490 first time users considering combined hormonal contraception.

The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. BMC Musculoskeletal Disorders.

This study found that joint replacement surgery for osteoarthritis is expected to rise by up to 276 per cent by 2030, costing Australia’s health care system over $5 billion.

Likelihood of knee replacement surgery up to 15 years after sports injury: A population-level data linkage study. Journal of Science & Medicine in Sport.

Data linkage study showing that having a knee injury more than doubled the likelihood of having knee replacement surgery within 15 years.


Forecasting the future burden of opioids for osteoarthritis. Osteoarthritis Cartilage.

Demonstrated the likely growth in use of opioid for osteoarthritis, despite limited evidence for their long-term use and the potential for opioid dependence and harms.

Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population‐Level Analysis. Arthritis Care & Research.

These projections provided tangible data that can be used by health funders and policy makers to plan future health service provision.

Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. Swiss Medical Weekly.

The economic and ethical rationales underpinning bariatric surgery for obesity and overweight was unknown due to a lack of evidence. Our HTA report provided evidence of health economic benefit.

Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. International Journal of Cardiology.

Provided evidence underpinning a Pharmaceutical Benefit Scheme policy decision to list rivaroxaban as first line treatment generating access for the Australian population being treated for cardiovascular disease.

Selection Bias and Outcomes for Preterm Neonates. Pediatrics.

Quantifies the characteristics of preterm neonates admitted to NICU and questions the role of current health service practice in admission bias.

Changes in out-of-pocket charges associated with obstetric care provided under Medicare in Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology.

Generated substantial media coverage including national syndication across Fairfax, NewsCorp and ABC, as well as AFT and Money Magazine.


Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Medical Weekly.

This model supported listing of sacubitril/valsartan in the Swiss Federal Office of Public Health and generated access for 15,491 patients treated with chronic heart failure.

A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. Journal of Thrombosis and Thrombolysis.

Out-of-pocket healthcare expenditure and chronic disease – do Australians forgo care due to the cost? Australian Journal of Primary Health.

Cited by Shadow Federal Minister for Health to support policy position on overturning the Medicare Rebate Freeze, which was ultimately successful. Generated sustained amount of media attention over a 5-year time period, and was the feature of an SBS Insight program in 2019.

A cost-effectiveness analysis of midwife psycho-education for fearful pregnant women – a health system perspective for the antenatal period. BMC Pregnancy and Childbirth.

Used to justify the increase in funding to upscale caseload midwifery in Queensland.

Hip and Knee Osteoarthritis Affects Younger People, Too. Journal of Orthopaedic & Sports Physical Therapy.

Highly-promoted Clinical Commentary, providing evidence-based management advice for physiotherapists who provide care for younger people with osteoarthritis.

The changing landscape of patient outcome assessment. Journal of Physiotherapy.

Editorial highlighting the use of patient-reported outcome measures to support value-based care.


Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective. Swiss Medical Weekly.

The economic and ethical rationales underpinning primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation were unknown due to a lack of evidence. Our HTA report provided evidence of no health economic benefit.

Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. Medicine.

First cost effectiveness study in Australia to provide evidence on superiority of Eplerenone compared to usual care in Heart Failure.

Chapter 36: Delivery - Organisation and outcome. Oxford Textbook of Osteoarthritis and Crystal Arthropathy (3rd edition). Oxford: Oxford University Press.

Chapter in the seminal osteoarthritis textbook summarising the organisation and delivery of care for osteoarthritis.

Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group. Arthritis Care & Research.

Invited role in the development of internationally-recognised recommendations for osteoarthritis outcome assessment that are now being implemented in health services around the world.

Is there a miss-match between who gets iron supplementation and who needs it? British Journal of Nutrition.

First study in Australia to identify that those who are most in need of iron supplementation – those with low income and migrant women – are the least likely to receive it. This made the case for an NHMRC funded randomised control trial which aims to change national guidelines for the treatment of iron deficient anaemia in pregnancy.

The lifetime impact of injury on education, employment and income. Occupational Medicine.

Quantifies the long-term economic burden of injury – used to underpin the design of cost-effectiveness analysis in multiple clinical trials.